Bayer vet Moeller to lead Antag

Antag Therapeutics ApS named Joerg Moeller CEO, as it takes GIPR antagonist AT-7687 into the clinic to treat obesity. Moeller previously served as head of global R&D at the pharmaceutical division of Bayer AG (Xetra:BAYN); he succeeds Alexander Sparre-Ulrich, who will become Antag’s COO. Last month, Antag raised an €80 million ($83.9 million) series A round led by Versant Ventures. 

Two companies announced CMO changes. Singapore-based Sunbird Bio Inc. hired Richard Batrla, who was VP and head of U.S. medical affairs at Eisai Co. Ltd. (Tokyo:4523). Batrla led the launch of Leqembi lecanemab to treat Alzheimer’s disease, for which Sunbird is developing an exosome-based test. ...